Page last updated: 2024-09-04

perifosine and quinazolines

perifosine has been researched along with quinazolines in 4 studies

Compound Research Comparison

Studies (perifosine)	Trials (perifosine)	Recent Studies (post-2010) (perifosine)	Studies (quinazolines)	Trials (quinazolines)	Recent Studies (post-2010) (quinazolines)
245	31	140	19,235	2,417	8,835

Protein Interaction Comparison

Protein	Taxonomy	perifosine (IC50)	quinazolines (IC50)
Epidermal growth factor receptor	Homo sapiens (human)		0.027

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C	1
Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA	1
Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L	1
Ho, WL; Wong, H; Yau, T	1

Reviews

2 review(s) available for perifosine and quinazolines

Article	Year
Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics : a review publication of the Radiological Society of North America, Inc, 2011, Volume: 31, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines	2011
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta ophthalmologica, 2013, Volume: 91, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab	2013

Article

Year

Genetics of glioblastoma: a window into its imaging and histopathologic variability.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2011, Volume: 31, Issue:6

Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines

2011

The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

Acta ophthalmologica, 2013, Volume: 91, Issue:7

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab

2013

Other Studies

2 other study(ies) available for perifosine and quinazolines

Article	Year
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. The Prostate, 2008, Jun-15, Volume: 68, Issue:9 Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Activation; Epidermal Growth Factor; Erlotinib Hydrochloride; Flow Cytometry; Humans; Male; Morpholines; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines	2008
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. International journal of oncology, 2012, Volume: 41, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptors, LHRH; Signal Transduction; Tamoxifen; TOR Serine-Threonine Kinases	2012

Article

Year

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.

The Prostate, 2008, Jun-15, Volume: 68, Issue:9

Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Activation; Epidermal Growth Factor; Erlotinib Hydrochloride; Flow Cytometry; Humans; Male; Morpholines; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines

2008

Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.

International journal of oncology, 2012, Volume: 41, Issue:5

Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptors, LHRH; Signal Transduction; Tamoxifen; TOR Serine-Threonine Kinases

2012